From SSTR to FAPI: Exploring a New Theranostic Pathway in Metastatic Grade 2 Gastrinoma with Loss of SSTR Expression
Indian Journal of Nuclear Medicine · 20.05.2026 · 41 · 361-363
DOI: 10.25259/ijnm_162_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Nuclear Medicine, online erschienen am 20.05.2026. Verfasst von G. B. Priyanka und 5 weiteren Autor:innen. Die Arbeit nennt 6 Literaturangaben.
Abstract (Originalsprache)
Somatostatin receptor (SSTR) PET/CT remains the cornerstone of imaging in neuroendocrine tumours (NETs), guiding both diagnosis and peptide receptor radionuclide therapy. However, dedifferentiated NETs may lose SSTR expression, limiting conventional theranostic approaches. In such cases, 18 F-fluorodeoxyglucose PET/CT can reveal metabolic heterogeneity; however, therapeutic options remain limited. Here, we present the imaging evidence of fibroblast activation protein inhibitor (FAPI) uptake in metastatic Grade 2 gastrinoma with loss of SSTR expression, providing FAPI as a potential alternative theranostic target in advanced NETs.
Zitieren
APA
Priyanka, G. B., Damle, N. A., Singh, A., Singh, A. N., Tripathi, M., & Rastogi, S. (2026). From SSTR to FAPI: Exploring a New Theranostic Pathway in Metastatic Grade 2 Gastrinoma with Loss of SSTR Expression. Indian Journal of Nuclear Medicine, 41, 361-363. https://doi.org/10.25259/ijnm_162_25
Vancouver
Priyanka GB, Damle NA, Singh A, Singh AN, Tripathi M, Rastogi S. From SSTR to FAPI: Exploring a New Theranostic Pathway in Metastatic Grade 2 Gastrinoma with Loss of SSTR Expression. Indian Journal of Nuclear Medicine. 2026;41:361-363. doi:10.25259/ijnm_162_25
BibTeX
@article{Priyanka2026,
author = {Priyanka, G. B. and Damle, Nishikant Avinash and Singh, Amandeep and Singh, Anand Narayan and Tripathi, Madhavi and Rastogi, Sameer},
title = {From SSTR to FAPI: Exploring a New Theranostic Pathway in Metastatic Grade 2 Gastrinoma with Loss of SSTR Expression},
journal = {Indian Journal of Nuclear Medicine},
year = {2026},
volume = {41},
pages = {361--363},
doi = {10.25259/ijnm_162_25}
}
EUVIMED